Alliance for Clinical Trials in Oncology

147 total trials 20 currently recruiting 88 completed

Trial Pipeline

RECRUITING NA

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT07059884

RECRUITING NA

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

NCT07091617

RECRUITING Phase 3

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

NCT06931340

RECRUITING Phase 3

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

NCT06876714

RECRUITING Phase 3

Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

NCT07000084

RECRUITING Phase 3

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

NCT06992427

RECRUITING Phase 3

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

NCT06661720

RECRUITING Phase 2

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

NCT06632977

RECRUITING Phase 3

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

NCT06632327

RECRUITING Phase 2

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

NCT05647265

RECRUITING Phase 3

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT05976763

RECRUITING Phase 3

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

NCT05673148

RECRUITING Phase 3

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

NCT05812807

RECRUITING Phase 3

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

NCT05677490

RECRUITING

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069

RECRUITING Phase 3

Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program

NCT05008848

RECRUITING Phase 3

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

NCT04939090

RECRUITING

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

NCT04242095

RECRUITING Phase 2

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

NCT03609216

RECRUITING Phase 2

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

NCT02523014

ACTIVE NOT RECRUITING Phase 2

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

NCT06115499

ACTIVE NOT RECRUITING Phase 2

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

NCT05710406

ACTIVE NOT RECRUITING Phase 2

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

NCT05303792

ACTIVE NOT RECRUITING Phase 2

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

NCT05694871

ACTIVE NOT RECRUITING Phase 2

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

NCT05247905

ACTIVE NOT RECRUITING Phase 3

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

NCT04711109

ACTIVE NOT RECRUITING Phase 2

Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation

NCT05610163

ACTIVE NOT RECRUITING Phase 2

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

NCT05241860

ACTIVE NOT RECRUITING Phase 3

Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy

NCT04989504

ACTIVE NOT RECRUITING Phase 3

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

NCT04637594

ACTIVE NOT RECRUITING Phase 3

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

NCT04455750

ACTIVE NOT RECRUITING Phase 3

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

NCT04457596

ACTIVE NOT RECRUITING NA

Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions

NCT04549571

ACTIVE NOT RECRUITING Phase 3

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

NCT04379570

ACTIVE NOT RECRUITING Phase 2

Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer

NCT04533451

ACTIVE NOT RECRUITING Phase 3

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

NCT04340141

ACTIVE NOT RECRUITING Phase 2

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

NCT04137107

ACTIVE NOT RECRUITING Phase 3

Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease

NCT04114981

ACTIVE NOT RECRUITING Phase 3

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

NCT04094688

ACTIVE NOT RECRUITING Phase 3

Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection

NCT03927027

ACTIVE NOT RECRUITING NA

Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer

NCT03857620

ACTIVE NOT RECRUITING Phase 2

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

NCT03944941

ACTIVE NOT RECRUITING NA

Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making

NCT03766009

ACTIVE NOT RECRUITING Phase 3

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

NCT03414970

ACTIVE NOT RECRUITING Phase 2

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

NCT03224767

ACTIVE NOT RECRUITING Phase 3

Breast Cancer WEight Loss Study (BWEL Study)

NCT02750826

ACTIVE NOT RECRUITING Phase 2

Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers

NCT02749903

ACTIVE NOT RECRUITING Phase 3

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

NCT01905046

ACTIVE NOT RECRUITING Phase 3

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors

NCT02375204

ACTIVE NOT RECRUITING Phase 2

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

NCT02143726

ACTIVE NOT RECRUITING Phase 3

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

NCT01953588

ACTIVE NOT RECRUITING Phase 3

Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy

NCT01901094

ACTIVE NOT RECRUITING Phase 2

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

NCT01511562

ACTIVE NOT RECRUITING Phase 3

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

NCT00887146

ACTIVE NOT RECRUITING Phase 3

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

NCT00430183

ACTIVE NOT RECRUITING

Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia

NCT00898456

ACTIVE NOT RECRUITING

Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia

NCT00003861

ACTIVE NOT RECRUITING

Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

NCT00899223

ACTIVE NOT RECRUITING

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma

NCT00048958

COMPLETED Phase 3

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

NCT03578081

COMPLETED Phase 3

Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers

NCT02349412

COMPLETED Phase 2

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

NCT01439711

COMPLETED

Studying Tumor Tissue Samples From Patients With Early-Stage Non-Small Cell Lung Cancer

NCT01517971

COMPLETED Phase 2

Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

NCT01190449

COMPLETED Phase 2

PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

NCT01333033

COMPLETED Phase 3

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349

COMPLETED Phase 3

Vitamin D and Breast Cancer Biomarkers in Female Patients

NCT01224678

COMPLETED Phase 2

Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

NCT01118026

COMPLETED Phase 2

Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

NCT01132807

COMPLETED Phase 2

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01027000

COMPLETED

DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701

NCT01057459

COMPLETED Phase 2

Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00881361

COMPLETED Phase 1

Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT00787969

COMPLETED Phase 2

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00798603

COMPLETED Phase 2

Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT00516217

COMPLETED Phase 3

Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00489411

COMPLETED Phase 3

Methylphenidate in Treating Patients With Fatigue Caused by Cancer

NCT00376675

COMPLETED Phase 2

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00454194

COMPLETED

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

NCT00516698

COMPLETED NA

Collection of Patient-Reported Symptoms and Performance Status Via the Internet

NCT00417040

COMPLETED

Assessing Older Patients With Cancer

NCT00416481

COMPLETED

Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies

NCT00897663

COMPLETED Phase 3

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

NCT00377156

COMPLETED Phase 2

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

NCT00310037

COMPLETED Phase 3

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery

NCT00316914

COMPLETED Phase 2

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00301821

COMPLETED Phase 2

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

NCT00098774

COMPLETED NA

Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer

NCT00089310

COMPLETED Phase 3

Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis

NCT00091351

COMPLETED Phase 2

Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma

NCT00086801

COMPLETED Phase 2

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

NCT00062114

COMPLETED

Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2

NCT00896701

COMPLETED Phase 2

Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease

NCT00074035

COMPLETED Phase 2

Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT00070486

COMPLETED Phase 2

Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction

NCT00054457

COMPLETED Phase 3

(Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy

NCT00075842

COMPLETED Phase 2

Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma

NCT00060333

COMPLETED Phase 1

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

NCT00049127

COMPLETED Phase 2

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

NCT00053196

COMPLETED Phase 3

Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer

NCT00052910

What the Pipeline for Alliance for Clinical Trials in Oncology Shows

According to the ClinicalTrials.gov registry, Alliance for Clinical Trials in Oncology is linked to 147 US clinical trials across every stage of research activity. Of those, 20 studies are currently recruiting — about 14% of the sponsor's indexed portfolio — and 88 are already marked complete, representing roughly 60% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Alliance for Clinical Trials in Oncology reports 52 late-stage studies (Phase 3 and Phase 4 combined) and 68 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Alliance for Clinical Trials in Oncology is Breast Cancer with 19 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial